Skip to main content

Table 1 Relationships between tumour characteristics and expression of mTOR and p-mTOR

From: Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

Clinicopathologic characteristics mTOR+ mTOR- P p-mTOR+ p-mTOR - P
  n(%) n(%)   n(%) n(%)  
Triple negative 22 (42.31%) 9 (17.31%) 0.03 24 (41.38%) 7 (12.07%) 0.0005
Non-triple negative 11 (21.15%) 16 (30.77%)   8 (13.79%) 19 (32.76%)  
Total 33 25   32 26  
    mTOR + 24 (41.38%) 8 (13.79%) 0.0032
    mTOR - 9 (17.31%) 17 (29.31%)  
     32 26  
    *    ***
HER2 + 7 (12.07%) 12 (20.69%) 0.0479 4 (6.9%) 15 (25.86%) 0.0005
HER2 - 26 (44.83%) 13 (22.41%)   28 (48.28%) 11 (18.97%)  
Total 33 25   32 26  
>1 cm 27 (46.55%) 16 (27.59%) >0.05 22 (42.31%) 20 (30.48%) 0.05
≤1 cm 8 (13.79%) 7 (12.07%)   10 (17.24%) 6 (10.34%)  
  35 23   32 26  
Grade I 5 (8.62%) 4 (6.90%) >0.05 4 (6.90%) 5 (8.62%) >0.05
Grade II 12 (20.69%) 12 (20.69%)   14 (24.14%) 10 (17.24%)  
Grade III 16 (27.59%) 9 (15.52%)   14 (24.14%) 11 (21.15%)  
Total 33 25   32 26  
Vascular invasion 7 (12.07%) 7 (12.07%) >0.05 6 (10.34%) 8 (13.79%) >0.05
No vascular invasion 26 (44.83%) 18 (31.03%)   26 (44.83%) 18 (31.03)  
Total 33 25   32 26  
Relapsed 25 (43.10%) 20 (30.48%) >0.05 17 (29.31%) 28 (48.28%) >0.05
Not relapsed 8 (13.79%) 5 (8.62%)   7 (12.07%) 6 (10.34%)  
Total 33 25   24 34  
Relapsed 0–6 months 17 (37.78%) 14 (31.11%) >0.05 9 (20.00%) 22 (48.89%) >0.05
Relapsed 6–12 months 4 (8.89%) 3 (31.03%)   4 (8.89%) 3 (31.03%)  
Relapsed >12 months 4 (8.89%) 3 (31.03%)   4 (8.89%) 4 (31.03%)  
Total 25 20   17 28  
Mitotic indexa 1 4 (6.90%) 2 (3.45%) >0.05 3 (5.17%) 3 (5.17%) >0.05
Mitotic index 2 7 (12.07%) 8 (13.79%)   8 (13.79%) 7 (12.07%)  
Mitotic index 3 22 (42.31%) 15 (25.86%)   21 (36.21%) 16 (27.59%)  
Total 33 25   32 26  
  1. aMitotic index of the histological grading system [27].